Aurobindo Pharma has appointed Sanjeev Dani, former senior executive with Ranbaxy Laboratories, as chief operating officer and head of formulation business. The company announced the appointment on Tuesday in a call with investors while declaring its results for the first quarter of the current fiscal.
Dani, who quit Ranbaxy in 2014, will lead the front-end operations of emerging markets and Europe at Aurobindo Pharma. He has replaced Arvind Vasudeva, who was in this role since November 2012.
Dani spent over a decade at Ranbaxy, managing various markets including India, the Middle East, Asia Pacific and Africa.
Aurobindo Pharma did not respond to an email sent by ET.
Dani was one of the key members of Ranbaxy's leadership team that got disbanded before Sun Pharmaceutical Industries acquired the company last year for $3.2 billion. Since the merger of Ranbaxy, Sun Pharma has been busy integrating the mammoth company with 15,000 employees. The integration has weighed heavily on Sun Pharma's quarterly revenues. As part of the integration, Sun Pharma in June gave marching orders to 18 senior level executives from Ranbaxy.